Analyst and Portfolio Manager at BB Biotech since 2014. Dr. Koch previously worked as a sell-side Pharma & Biotech Equity Analyst at Bank am Bellevue and Research Associate at the Institute of Pharmaceutical Sciences, ETH Zurich. He holds a PhD in Chemoinformatics & Computational Drug Design from ETH Zurich and a Masters in Bioinformatics from Goethe University Frankfurt.
Success in challenging fixed income markets requires an approach that is truly unconstrained.
Nick Payne, head of global emerging markets at Old Mutual Global Investors, feels more sanguine about his asset class now that the exuberant start to 2018 has eased.
When faced with a crossroads in the market, it may pay to be cautious about forecasting macro, argues Ian Heslop, head of global equities at OMGI and manager of the Old Mutual North American Equity Fund
Sovereigns and corporate fixed income investments are inextricably linked through economic and market forces. Too often a country’s economic risk profile can be mispriced in fixed income markets due segmentation of these sectors
The proliferation of smart beta in equity, leads to the question of whether smart strategies can be utilised in fixed income. Rules based investors are often the source of inefficiency in fixed income markets and to us a smart strategy requires an active component
We find inefficiencies in markets using a series of strategies that maximise returns for a given level of risk.
Misconceptions around ‘emerging’ and ‘developed’ markets have resulted in mispricing of risk leading to considerable opportunities for the well-informed investor.
Bond indices were never intended to form a basis for investment but merely reflect a market. As a consequence, they expose investors to unintended risks and are not a rational investment strategy.
Schroder’s Andrew Howard believes many investors are ill prepared for the investment risk that climate change will bring. The firm’s new Carbon Value at Risk analysis has been developed to meet the challenges ahead.